Reprogramming gets a splicing factor and a three-patient human signal — while GLP-1 frailty data stay hypothesis-generating
Two partial-rejuvenation stories land together with very different evidence weight: AAV-delivered SRSF1 extends median lifespan about 14% in aged mice (peer-reviewed, Nature Aging), whereas Life Biosciences' first human ER-100 readout is a company press release covering three open-label patients at Day 56. The most clinically useful item is a post hoc SELECT analysis showing semaglutide's cardiovascular benefit does not vary by frailty-index stratum, which is explicitly hypothesis-generating and does not show preserved physical function. Several rodent lifespan and healthspan claims this week (senolytic nanovaccine, FGF13, KIF2C agonist) come with small n, short-lived controls, or progeria-only models and should be read as proof-of-concept.
Median lifespan extension in aged mice with liver-targeted AAV-SRSF1 (Nature Aging 2026; mouse only, per press coverage — sample sizes not verified)
Where the human evidence is
Count by statusEvidence-stage map
Evidence stage × investigator promise (1–10)Partial reprogramming and rejuvenation
Transcriptomic reprogramming screen identifies SRSF1 as a regulator of aging; AAV-SRSF1 extends median lifespan ~14% in mice
Church lab (Wyss) and del Sol group trained a transcriptomic-age predictor on human fibroblasts, screened age-related genes in aged fibroblasts, and ranked the splicing factor SRSF1 highest. Rejuvenated cells reportedly retained fibroblast identity without activating pluripotency programs, with reduced senescence and inflammatory signaling and restored DNA-repair programs. Liver-tropic AAV-SRSF1 reportedly raised median lifespan about 14% in aged mice. Sample sizes, sexes, survival curves and the epigenetic-clock magnitude were not available to verify; delivery, dosing and mechanism (alternative splicing) remain open and there are no human in vivo data.
Read the paperLife Biosciences reports first-in-human interim data for ER-100 (inducible OSK) in optic neuropathies
ER-100 is an AAV2-delivered, doxycycline-inducible OSK partial-reprogramming therapy given as a single intravitreal injection with 8 weeks of oral doxycycline and a prednisolone taper. The sponsor reports it was well tolerated through Day 56 in three participants with no dose-limiting toxicities or serious adverse events, and visual-field improvement in 2 of 3 open-angle glaucoma patients (at least 28% of points improved by more than 4 dB). This is a safety-focused interim readout with no control arm, a very short follow-up, and no peer review: it is a feasibility signal, not evidence of efficacy.
Read the paperNeuro-longevity: lipid signalling and astrocytes
Suppressing neural stem cell PLA2G7 restores inhibitory circuit function and improves cognition in aging mice
PLA2G7, a secreted lipid-metabolizing enzyme expressed by neural stem cells, acts as a negative regulator of inhibitory circuit function in the dentate gyrus; the fraction of PLA2G7+ NSCs rose from about 56% at 2 months to about 72% at 14 months. Deletion in NSCs, or suppression in aged mice, increased inhibitory input onto granule cells and improved hippocampal-dependent cognition, with PLA2G7-dependent phospholipid changes and in vitro rescue by phosphatidylcholine. Mouse-only; durability, safety and translation of PLA2G7 inhibition were not addressed in the material accessed (abstract and extended-data legends).
Read the paperAstrocytic FGF13 slows whole-body aging markers in mice (modest effects)
Astrocyte-specific FGF13 knockout accelerated aging phenotypes (worse water-maze performance, more senescence in peripheral tissues, higher circulating cytokines), while overexpression in older mice improved cognition and lowered IFN-gamma and IL-6 and tissue senescence markers. No lifespan extension was reported, benefits were described as significant but modest, heart senescence was unchanged, and no strategy for raising FGF13 in humans is proposed. Primary-paper details were not directly verified.
Read the paperComparative biology, metabolism and mitochondrial targets
Cold-induced longevity in C. elegans requires muscle-derived BH2 and tyrosine production
Worms held about 5 degrees C below the standard 20 degrees C reportedly lived roughly 15% longer; BH2 rose in the cold, blocking its production abolished the benefit, and tyrosine feeding extended lifespan in BH2-deficient worms at standard temperature. In human neurons BH2 reportedly improved resistance to aggregation-prone proteins. Invertebrate model, mechanism through redox-sensitive cofactor biology could cut both ways, and the investigators and commentators caution against supplementation inferences from this work.
Read the paperTopical urolithin A activates mitophagy and reduces periorbital wrinkle depth and UVB erythema in randomized placebo-controlled studies
In reconstructed 2D/3D human skin and ex vivo explants, topical urolithin A increased mitochondrial respiration and mitophagy markers and reduced inflammatory and senescence markers. In randomized placebo-controlled studies in healthy volunteers it reduced periorbital wrinkle depth at 8 weeks and attenuated UVB-induced erythema. This is a cosmetic/skin-function surrogate in an apparently small cohort, and funding and conflicts of interest were not verified; it does not support systemic anti-aging claims for oral urolithin A.
Read the paper